Oppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with ...
Oppenheimer’s Jack Quaid On The ‘Favorite’ Moment He ‘Never In A Million Years Thought’ He’d Have With Director Christopher Nolan
Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...
Joshua Oppenheimer on why he’s made a post-apocalyptic musical: ‘It’s much bigger than climate change’
The director of ‘The End’ discusses getting tips from Werner Herzog and how contemplating catastrophe can make us more human ...
Oppenheimer Downgrades Goldman, Says M&A Rebound ‘Delayed or Cancelled’
Key Takeaways The mergers & acquisitions bounce investors expected after President Donald Trump’s return to the White House ...
Oppenheimer slashes 2025 US investment banking forecast on tariff worries
Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...
The ‘Oppenheimer Moment’ That Looms Over Today’s AI Leaders
Such an advance, leaders agree, would fundamentally transform society. Google CEO Sundar Pichai has repeatedly described AI ...
Opthea downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Opthea (OPT) to Perform from Outperform.Light Up your Portfolio with Spark:Easily identify stocks' risks and ...
Jewish Telegraphic Agency6d
The Jewish story behind ‘Oppenheimer,’ explained
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)
Oppenheimer started coverage on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report released on Monday, ...
Oppenheimer upgrades Mosaic on cost cuts and portfolio optimization
Oppenheimer upgraded The Mosaic Company (NYSE:MOS) to Outperform from Perform and set a price target of $33 given the fertilizer maker’s efforts to reduce costs, optimize its product portfolio, and ...
Lam Research initiated with Outperform rating on long-term value: Oppenheimer
Lam Research (NASDAQ:LRCX) received an Outperform rating as financial services firm Oppenheimer initiated coverage of the ...